A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
16th Oct 2023 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, has successfully completed treatment of the first two dose levels of the Dose-escalation phase, with four patients treated once daily prior to Radiotherapy for 24 weeks collectively. NG11-2 is well tolerated with no Dose-Limiting Toxicities reported as yet, and an early indication of improved clinical readouts at the higher dose level . The treatment with the third dose level of NG11-2 commenced this week.
The study is investigating the safety and preliminary efficacy of NG11-2 mouthwash for reducing and preventing severe Radiation-Induced Oral Mucositis (RIOM), a well-known and debilitating side-effect of radiotherapy on patients undergoing treatment for head & neck cancer. The study consists of the dose escalation phase followed by a dose expansion phase on the recommended phase 2 dose (RP2D) that is to be chosen following the dose escalation phase.
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
“We are delighted with the successful completion of treatment at the first two dose levels, which showed good tolerability and preliminary dose-dependent effectiveness. This represents an exciting milestone in the progress of our NG11-2 Phase-Ib trial. We are looking forward to seeing the data from the remaining higher dose level treatments which started this week”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO +44 7969132263
Gary Bower, COO +44 7960388412
Notes to Editors:
VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating, and often dose-limitin,g complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment whilst facilitating anti-cancer therapy efficacy.